

Table S1. Incidence of adverse events (AEs) in elderly psoriatic patients treated with systemic therapies

AEs	Methotrexate (n = 74)	Acitretin (n = 62)	Cyclosporine (n = 36)	PUVA (n = 14)	Etanercept (n = 83)	Adalimumab (n = 18)	Infliximab (n = 16)	Efalizumab (n = 14)	Ustekinumab (n = 4)
Infections	1 (1.3%)	-	-	-	7 (8.4%)	3 (16.7%)	2 (12.5%)	-	-
Serious	-	-	-	-	2 (1 pneumonia ^a , 1 herpes zoster ^a)	-	1 pneumonia ^a	-	-
Non serious	1 herpes zoster	-	-	-	5 (3 cystitis, 1 otitis, 1 HSV infection)	3 (2 cystitis, 1 HSV infection)	-	-	-
Neoplastic diseases	1 (1.3%) ovarian carcinoma ^a	-	-	2 (11.7%) skin SCC	1 (1.2%) anaplastic cutaneous lymphoma	-	-	1 (7.1%) breast carcinoma ^a	-
Other SAEs	1 AMI ^a	-	-	-	3 (1 atrial fibrillation ^a , 1 myasthenia gravis ^a , 1 pericarditis ^a)	-	2 (1 AMI ^a , 1 thromboembolism ^a)	-	-
Other AEs	3 anaemia 2 asthenia 1 epigastralgia	6 increased STG 4 skin xerosis 4 liver enzyme rise 1 alopecia	11 hypertension 5 renal insufficiency 2 asthenia 2 epigastralgia	2 erythema	2 increased GTP 1 increased STG 2 injection site reactions	1 increased STG 1 increased total cholesterol 1 liver enzyme rise 1 headache 1 epilepsy 1 asthenia	1 diabetes 1 body weight increase 1 increased ANA levels	1 arthritis 1 headache 1 lymphocytosis	1 increased STG
Total	9 (12.2%)	15 (24.2%)	20 (55.5%)	4 (28.5%)	16 (19.2%)	9 (50%)	7 (43.75%)	4 (28.6%)	1 (25%)

^aSevere case that needed hospitalisation.

AMI: acute myocardial infarction; ANA: antinuclear antibodies; GTP: glutamyl transpeptidase; HSV: herpes simplex virus; SAE: serious adverse event; SCC: squamous cell carcinoma; STG: serum triglycerides.